ALK and non-small cell lung carcinoma: Pioneering biomarker approved therapies include: HER2 in breast cancer,7 BCR‐ABL in chronic myelogenous lymphoma,8 anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangements in NSCLC,9 BRAF V600 mutations in melanoma10 and the absence of RAS mutations in colorectal cancer.11